Vasyl Zhabotynsky
Research Subjects
Research Interests
Vasyl Zhabotynsky has a total of 219 co-authors. Here are the top co-authors by number of shared publications:
- Fernando Pardo-Manuel de Villena
University of North Carolina at Chapel Hill
7 shared publications - James Joseph Crowley
Department of Genetics, University of North Carolina at Chapel Hill, Chapel Hill, NC, USA
6 shared publications - Wei Sun
Fred Hutchinson Cancer Center
6 shared publications Fei Zou
Department of Biostatistics, University of North Carolina at Chapel Hill
5 shared publications- Brian C. Miller
Lineberger Comprehensive Cancer Center, University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, USA
4 shared publications - Darla R. Miller
University of North Carolina at Chapel Hill
4 shared publications
Latest Publications
- Open Access
- 4 November 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (11) , e015096
Harnessing inflammatory monocytes to overcome resistance to anti-PD-1 immunotherapy
- 4 November 2026
- Published by BMJ in Journal for ImmunoTherapy of Cancer
- Vol. 14 (11) , e015096
Open AccessHarnessing inflammatory monocytes to overcome resistance to anti-PD-1 immunotherapy
- Open Access
Folate metabolism in tumor-associated macrophages drives immunosuppressive function to promote tumor growth
Tumor-associated macrophages (TAMs) promote tumor progression, inhibit anti-tumor immunity, and induce resistance to immune checkpoint inhibitors (ICI). Metabolism is a primary determinant of TAM polarization, suggesting therapies that selectively modulate TAM metabolic state may hold therapeutic benefit. Here we demonstrate folate uptake and metabolism sustained by the myeloid-restricted folate receptor beta (FRβ) are critical for TAM immunosuppressive function. Folate was depleted in the microenvironment of human melanomas, suggesting FRβ upregulation by TAMs may be an adaptive response to folate scarcity. FRβ⁺ TAMs exhibited an immunosuppressive phenotype and were associated with immunotherapy resistance in melanoma patients. Genetic ablation of FRβ attenuated tumor growth across multiple cancer models and repolarized macrophages toward pro-inflammatory states, promoting tumor infiltration by activated lymphocytes. Critically, excess folate reversed the phenotypes observed with FRβ loss, suggesting these effects stem from impaired folate uptake by TAMs rather than a folate-independent role for FRβ. Integrated metabolomic, transcriptomic, and functional mechanistic studies demonstrated that folate acquisition via FRβ was required to generate reduced glutathione to limit mitochondrial reactive oxygen species (ROS) production. In the absence of FRβ, mitochondrial oxidative stress promoted canonical NF-kB signaling and macrophage pro-inflammatory polarization. Thus, FRβ couples a nutrient-limited microenvironment to TAM immunosuppressive function and represents a therapeutically tractable metabolic checkpoint for TAMs.
Open AccessFolate metabolism in tumor-associated macrophages drives immunosuppressive function to promote tumor growth
Tumor-associated macrophages (TAMs) promote tumor progression, inhibit anti-tumor immunity, and induce resistance to immune checkpoint inhibitors (ICI). Metabolism is a primary determinant of TAM polarization, suggesting therapies that selectively modulate TAM metabolic state may hold therapeutic benefit. Here we demonstrate folate uptake and metabolism sustained by the myeloid-restricted folate receptor beta (FRβ) are critical for TAM immunosuppressive function. Folate was depleted in the microenvironment of human melanomas, suggesting FRβ upregulation by TAMs may be an adaptive response to folate scarcity. FRβ⁺ TAMs exhibited an immunosuppressive phenotype and were associated with immunotherapy resistance in melanoma patients. Genetic ablation of FRβ attenuated tumor growth across multiple cancer models and repolarized macrophages toward pro-inflammatory states, promoting tumor infiltration by activated lymphocytes. Critically, excess folate reversed the phenotypes observed with FRβ loss, suggesting these effects stem from impaired folate uptake by TAMs rather than a folate-independent role for FRβ. Integrated metabolomic, transcriptomic, and functional mechanistic studies demonstrated that folate acquisition via FRβ was required to generate reduced glutathione to limit mitochondrial reactive oxygen species (ROS) production. In the absence of FRβ, mitochondrial oxidative stress promoted canonical NF-kB signaling and macrophage pro-inflammatory polarization. Thus, FRβ couples a nutrient-limited microenvironment to TAM immunosuppressive function and represents a therapeutically tractable metabolic checkpoint for TAMs.
- Open Access
- 11 June 2026
- Published by Springer Nature in Research Square
Single-cell gain-of-function mapping reveals latent regulatory programs governing CD8+ T cell fate
CD8⁺ T cells mediate host defense and tumor immunity through specialized differentiation states, yet the regulatory programs that guide these states may also limit their functional potential. Loss-of-function studies have defined many regulators required for T cell differentiation, but they do not readily reveal regulatory activities that emerge only when transcription factors are ectopically expressed outside their native lineage, dosage, or temporal context. Here, we developed single-cell gain-of-functon(GOF) sequencing (scGOF-seq), a multiplexed platform for in vivo mapping of transcription factor overexpression in antigen-specific CD8⁺ T cells across immunocompetent models of infection and cancer. By enforcing expression of canonical T cell regulators, lineage-silenced developmental factors, and temporally restricted transcription factors, scGOF-seq uncovered unexpected in vivo activities. Developmental regulators normally silenced in T cells, including NANOG, SOX2, OCT4 and GATA2, reshaped T cell differentiation in context-dependent ways, with NANOG promoting stemness-associated phenotypes and accumulation during chronic infection. In parallel, sustained cMyc expression outside its native temporal window generated a stem-like, effector-featured state with enhanced metabolic fitness, reduced terminal exhaustion, and profound antigen-dependent expansion exceeding 5,000-fold. Importantly, cMyc GOF maintained cell-cycle checkpoint signatures and demonstrated a strong dependence on antigen presence for proliferation across the tested conditions. scGOF-seq further identified cooperating transcription factor modules that complemented cMyc-driven programs and improved T cell responses in solid tumors. These findings establish systematic GOF perturbation as a framework for uncovering latent and temporally constrained regulatory activities in CD8⁺ T cells and guiding immune-state engineering.
- 11 June 2026
- Published by Springer Nature in Research Square
Open AccessSingle-cell gain-of-function mapping reveals latent regulatory programs governing CD8+ T cell fate
CD8⁺ T cells mediate host defense and tumor immunity through specialized differentiation states, yet the regulatory programs that guide these states may also limit their functional potential. Loss-of-function studies have defined many regulators required for T cell differentiation, but they do not readily reveal regulatory activities that emerge only when transcription factors are ectopically expressed outside their native lineage, dosage, or temporal context. Here, we developed single-cell gain-of-functon(GOF) sequencing (scGOF-seq), a multiplexed platform for in vivo mapping of transcription factor overexpression in antigen-specific CD8⁺ T cells across immunocompetent models of infection and cancer. By enforcing expression of canonical T cell regulators, lineage-silenced developmental factors, and temporally restricted transcription factors, scGOF-seq uncovered unexpected in vivo activities. Developmental regulators normally silenced in T cells, including NANOG, SOX2, OCT4 and GATA2, reshaped T cell differentiation in context-dependent ways, with NANOG promoting stemness-associated phenotypes and accumulation during chronic infection. In parallel, sustained cMyc expression outside its native temporal window generated a stem-like, effector-featured state with enhanced metabolic fitness, reduced terminal exhaustion, and profound antigen-dependent expansion exceeding 5,000-fold. Importantly, cMyc GOF maintained cell-cycle checkpoint signatures and demonstrated a strong dependence on antigen presence for proliferation across the tested conditions. scGOF-seq further identified cooperating transcription factor modules that complemented cMyc-driven programs and improved T cell responses in solid tumors. These findings establish systematic GOF perturbation as a framework for uncovering latent and temporally constrained regulatory activities in CD8⁺ T cells and guiding immune-state engineering.
- Open Access
Harnessing Inflammatory Monocytes to Overcome Resistance to Anti-PD-1 Immunotherapy
Background: Resistance to immune checkpoint inhibitors represents a major therapeutic challenge, as less than 50% of patients with melanoma achieve long-term response to immune checkpoint inhibitor therapy. One mechanism of acquired resistance involves somatic mutations, such as loss of beta-2 microglobulin ( B2m ), that enable tumor cells to evade T cell-mediated killing. Methods: This study used single-cell RNA-seq, flow cytometry, and ex vivo functional assays to characterize tumor-infiltrating immune cells in antigen presentation-deficient tumors. Tumor-bearing mice were treated with anti-PD-1 or CD40 agonist antibodies and cell depletion or cytokine blocking antibodies to define mechanisms of action. Analysis of published human RNA-seq datasets was performed to dissect the contributions of inflammatory monocytes to patient outcomes. Results: We found an increase in immunosuppressive macrophages in B2m -null tumors. We hypothesized that repolarizing myeloid cells may restore control of tumor growth. Treatment with CD40 agonist antibody, which promotes differentiation of monocytes and macrophages towards a proinflammatory phenotype, reduced tumor growth and improved survival in B2m -null melanoma and colorectal cancer models. Unexpectedly, both CD8 + T cells and NK cells, but not CD4 + T cells, were required for the efficacy of CD40 agonist, even though CD8 + T cells cannot directly recognize antigen presentation-deficient tumor cells. Instead, these lymphocytes control tumor growth via secretion of IFNγ, as depletion of IFNγ inhibited the therapeutic effect of CD40 agonist. IFNγ receptor ( Ifngr1 ) expression was required on host cells, not tumor cells, for CD40 agonist-mediated tumor control. Single-cell analysis identified a distinct population of inflammatory monocytes that were enriched for an IFNγ response signature in CD40 agonist-treated tumors, suggesting that these cells may be important for tumor control. Analysis of human bulk and single-cell RNA-seq datasets demonstrated that an inflammatory monocyte signature derived from our data was associated with improved patient outcomes and response to immune checkpoint inhibitors. Conclusions: These data demonstrate that CD8 + T cells contribute to tumor control even in the absence of direct antigen presentation by tumor cells. More broadly, our work suggests that strategies to activate the effector functions of inflammatory monocytes may limit tumor growth and overcome acquired resistance to immune checkpoint inhibitors.
Open AccessHarnessing Inflammatory Monocytes to Overcome Resistance to Anti-PD-1 Immunotherapy
Background: Resistance to immune checkpoint inhibitors represents a major therapeutic challenge, as less than 50% of patients with melanoma achieve long-term response to immune checkpoint inhibitor therapy. One mechanism of acquired resistance involves somatic mutations, such as loss of beta-2 microglobulin ( B2m ), that enable tumor cells to evade T cell-mediated killing. Methods: This study used single-cell RNA-seq, flow cytometry, and ex vivo functional assays to characterize tumor-infiltrating immune cells in antigen presentation-deficient tumors. Tumor-bearing mice were treated with anti-PD-1 or CD40 agonist antibodies and cell depletion or cytokine blocking antibodies to define mechanisms of action. Analysis of published human RNA-seq datasets was performed to dissect the contributions of inflammatory monocytes to patient outcomes. Results: We found an increase in immunosuppressive macrophages in B2m -null tumors. We hypothesized that repolarizing myeloid cells may restore control of tumor growth. Treatment with CD40 agonist antibody, which promotes differentiation of monocytes and macrophages towards a proinflammatory phenotype, reduced tumor growth and improved survival in B2m -null melanoma and colorectal cancer models. Unexpectedly, both CD8 + T cells and NK cells, but not CD4 + T cells, were required for the efficacy of CD40 agonist, even though CD8 + T cells cannot directly recognize antigen presentation-deficient tumor cells. Instead, these lymphocytes control tumor growth via secretion of IFNγ, as depletion of IFNγ inhibited the therapeutic effect of CD40 agonist. IFNγ receptor ( Ifngr1 ) expression was required on host cells, not tumor cells, for CD40 agonist-mediated tumor control. Single-cell analysis identified a distinct population of inflammatory monocytes that were enriched for an IFNγ response signature in CD40 agonist-treated tumors, suggesting that these cells may be important for tumor control. Analysis of human bulk and single-cell RNA-seq datasets demonstrated that an inflammatory monocyte signature derived from our data was associated with improved patient outcomes and response to immune checkpoint inhibitors. Conclusions: These data demonstrate that CD8 + T cells contribute to tumor control even in the absence of direct antigen presentation by tumor cells. More broadly, our work suggests that strategies to activate the effector functions of inflammatory monocytes may limit tumor growth and overcome acquired resistance to immune checkpoint inhibitors.
- Open Access
- 8 May 2024
- Published by Springer Nature in Research Square
Retinopathy of prematurity and neurodevelopmental outcome and quality of life at 10 years of age
Objective In a cohort of 10-year-old children born extremely preterm, we evaluated the hypothesis that increasing severity of retinopathy of prematurity (ROP) is associated with increasing frequency of unfavorable neurodevelopmental and quality of life outcomes. Study Design Study participants were classified according to the severity of ROP. At 10 years of age, their neurocognitive abilities, academic achievement, and gross motor function were assessed, and they were evaluated for autism spectrum disorder, anxiety, depression, and quality of life. Results After adjustment for sample attrition and confounders, only the association with lower quality of life persisted. Increasing severity of visual impairment was associated with worse neurodevelopmental outcomes and lower quality of life. Conclusion Among extremely preterm children, severity of visual impairment, but not severity of ROP, was associated with adverse neurodevelopmental outcomes at 10 years of age. Both severe ROP and more severe visual impairment were associated with lower quality of life.
- 8 May 2024
- Published by Springer Nature in Research Square
Open AccessRetinopathy of prematurity and neurodevelopmental outcome and quality of life at 10 years of age
Objective In a cohort of 10-year-old children born extremely preterm, we evaluated the hypothesis that increasing severity of retinopathy of prematurity (ROP) is associated with increasing frequency of unfavorable neurodevelopmental and quality of life outcomes. Study Design Study participants were classified according to the severity of ROP. At 10 years of age, their neurocognitive abilities, academic achievement, and gross motor function were assessed, and they were evaluated for autism spectrum disorder, anxiety, depression, and quality of life. Results After adjustment for sample attrition and confounders, only the association with lower quality of life persisted. Increasing severity of visual impairment was associated with worse neurodevelopmental outcomes and lower quality of life. Conclusion Among extremely preterm children, severity of visual impairment, but not severity of ROP, was associated with adverse neurodevelopmental outcomes at 10 years of age. Both severe ROP and more severe visual impairment were associated with lower quality of life.
- Open Access
- 25 May 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-13
A computational method for cell type-specific expression quantitative trait loci mapping using bulk RNA-seq data
Mapping cell type-specific gene expression quantitative trait loci (ct-eQTLs) is a powerful way to investigate the genetic basis of complex traits. A popular method for ct-eQTL mapping is to assess the interaction between the genotype of a genetic locus and the abundance of a specific cell type using a linear model. However, this approach requires transforming RNA-seq count data, which distorts the relation between gene expression and cell type proportions and results in reduced power and/or inflated type I error. To address this issue, we have developed a statistical method called CSeQTL that allows for ct-eQTL mapping using bulk RNA-seq count data while taking advantage of allele-specific expression. We validated the results of CSeQTL through simulations and real data analysis, comparing CSeQTL results to those obtained from purified bulk RNA-seq data or single cell RNA-seq data. Using our ct-eQTL findings, we were able to identify cell types relevant to 21 categories of human traits.
- 25 May 2023
- Published by Springer Nature in Nature Communications
- Vol. 14 (1) , 1-13
Open AccessA computational method for cell type-specific expression quantitative trait loci mapping using bulk RNA-seq data
Mapping cell type-specific gene expression quantitative trait loci (ct-eQTLs) is a powerful way to investigate the genetic basis of complex traits. A popular method for ct-eQTL mapping is to assess the interaction between the genotype of a genetic locus and the abundance of a specific cell type using a linear model. However, this approach requires transforming RNA-seq count data, which distorts the relation between gene expression and cell type proportions and results in reduced power and/or inflated type I error. To address this issue, we have developed a statistical method called CSeQTL that allows for ct-eQTL mapping using bulk RNA-seq count data while taking advantage of allele-specific expression. We validated the results of CSeQTL through simulations and real data analysis, comparing CSeQTL results to those obtained from purified bulk RNA-seq data or single cell RNA-seq data. Using our ct-eQTL findings, we were able to identify cell types relevant to 21 categories of human traits.
- Open Access
A computational method for Cell type-specific Expression Quantitative Trait Loci mapping using bulk RNA-seq data
Mapping cell type-specific gene expression quantitative trait loci (ct-eQTLs) is a powerful way to investigate the genetic basis of complex traits. A popular method for ct-eQTL mapping is to assess the interaction between the genotype of a genetic locus and the abundance of a specific cell type using a linear model. However, this approach requires transforming RNA-seq count data, which distorts the relation between gene expression and cell type proportions and results in reduced power and/or inflated type I error. To address this issue, we have developed a statistical method called CSeQTL that allows for ct-eQTL mapping using bulk RNA-seq count data while taking advantage of allele-specific expression. We validated the results of CSeQTL through simulations and real data analysis, comparing CSeQTL results to those obtained from purified bulk RNA-seq data or single cell RNA-seq data. Using our ct-eQTL findings, we were able to identify cell types relevant to 21 categories of human traits.
Open AccessA computational method for Cell type-specific Expression Quantitative Trait Loci mapping using bulk RNA-seq data
Mapping cell type-specific gene expression quantitative trait loci (ct-eQTLs) is a powerful way to investigate the genetic basis of complex traits. A popular method for ct-eQTL mapping is to assess the interaction between the genotype of a genetic locus and the abundance of a specific cell type using a linear model. However, this approach requires transforming RNA-seq count data, which distorts the relation between gene expression and cell type proportions and results in reduced power and/or inflated type I error. To address this issue, we have developed a statistical method called CSeQTL that allows for ct-eQTL mapping using bulk RNA-seq count data while taking advantage of allele-specific expression. We validated the results of CSeQTL through simulations and real data analysis, comparing CSeQTL results to those obtained from purified bulk RNA-seq data or single cell RNA-seq data. Using our ct-eQTL findings, we were able to identify cell types relevant to 21 categories of human traits.
- Open Access
- 14 March 2022
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 18 (3) , e1010076
eQTL mapping using allele-specific count data is computationally feasible, powerful, and provides individual-specific estimates of genetic effects
Using information from allele-specific gene expression (ASE) can improve the power to map gene expression quantitative trait loci (eQTLs). However, such practice has been limited, partly due to computational challenges and lack of clarification on the size of power gain or new findings besides improved power. We have developed geoP, a computationally efficient method to estimate permutation p-values, which makes it computationally feasible to perform eQTL mapping with ASE counts for large cohorts. We have applied geoP to map eQTLs in 28 human tissues using the data from the Genotype-Tissue Expression (GTEx) project. We demonstrate that using ASE data not only substantially improve the power to detect eQTLs, but also allow us to quantify individual-specific genetic effects, which can be used to study the variation of eQTL effect sizes with respect to other covariates. We also compared two popular methods for eQTL mapping with ASE: TReCASE and RASQUAL. TReCASE is ten times or more faster than RASQUAL and it provides more robust type I error control.
- 14 March 2022
- Published by Public Library of Science (PLoS) in PLOS Genetics
- Vol. 18 (3) , e1010076
Open AccesseQTL mapping using allele-specific count data is computationally feasible, powerful, and provides individual-specific estimates of genetic effects
Using information from allele-specific gene expression (ASE) can improve the power to map gene expression quantitative trait loci (eQTLs). However, such practice has been limited, partly due to computational challenges and lack of clarification on the size of power gain or new findings besides improved power. We have developed geoP, a computationally efficient method to estimate permutation p-values, which makes it computationally feasible to perform eQTL mapping with ASE counts for large cohorts. We have applied geoP to map eQTLs in 28 human tissues using the data from the Genotype-Tissue Expression (GTEx) project. We demonstrate that using ASE data not only substantially improve the power to detect eQTLs, but also allow us to quantify individual-specific genetic effects, which can be used to study the variation of eQTL effect sizes with respect to other covariates. We also compared two popular methods for eQTL mapping with ASE: TReCASE and RASQUAL. TReCASE is ten times or more faster than RASQUAL and it provides more robust type I error control.
- Open Access
eQTL mapping using allele-specific gene expression
Using information from allele-specific gene expression (ASE) can sub-stantially improve the power to map gene expression quantitative trait loci (eQTLs). However, such practice has been limited, partly due to high computational cost and the requirement to access raw data that can take a large amount of storage space. To address these computational challenges, we have developed a computational framework that uses a statistical method named TReCASE as its computational engine, and it is computationally feasible for large scale analysis. We applied it to map eQTLs in 28 human tissues using the data from the Genotype-Tissue Expression (GTEx) project. Compared with a popular linear regression method that does not use ASE data, TReCASE can double the number of eGenes (i.e., genes with at least one significant eQTL) when sample size is relatively small, e.g., n = 200. We also demonstrated how to use the ASE data that we have collected to study dynamic eQTLs whose effect sizes vary with respect to another variable, such as age. We find the majority of such dynamic eQTLs are due to some underlying latent factors, such as cell type proportions. We further compare TReCASE versus another method RASQUAL. TReCASE is ten times or more faster than RASQUAL and it provides more robust type I error control.
Open AccesseQTL mapping using allele-specific gene expression
Using information from allele-specific gene expression (ASE) can sub-stantially improve the power to map gene expression quantitative trait loci (eQTLs). However, such practice has been limited, partly due to high computational cost and the requirement to access raw data that can take a large amount of storage space. To address these computational challenges, we have developed a computational framework that uses a statistical method named TReCASE as its computational engine, and it is computationally feasible for large scale analysis. We applied it to map eQTLs in 28 human tissues using the data from the Genotype-Tissue Expression (GTEx) project. Compared with a popular linear regression method that does not use ASE data, TReCASE can double the number of eGenes (i.e., genes with at least one significant eQTL) when sample size is relatively small, e.g., n = 200. We also demonstrated how to use the ASE data that we have collected to study dynamic eQTLs whose effect sizes vary with respect to another variable, such as age. We find the majority of such dynamic eQTLs are due to some underlying latent factors, such as cell type proportions. We further compare TReCASE versus another method RASQUAL. TReCASE is ten times or more faster than RASQUAL and it provides more robust type I error control.